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Abstract
Proton magnetic resonance spectroscopy (1H MRS) is a valuable tool in Alzheimer’s disease research, investigating the
functional integrity of the brain. The present longitudinal study set out to characterize the neurochemical profile of the
hippocampus, measured by single voxel 1H MRS at 7 Tesla, in the brains of AbPPSswe-PS1dE9 and wild-type mice at 8 and
12 months of age. Furthermore, we wanted to determine whether alterations in hippocampal metabolite levels coincided
with behavioral changes, cognitive decline and neuropathological features, to gain a better understanding of the
underlying neurodegenerative processes. Moreover, correlation analyses were performed in the 12-month-old AbPP-PS1
animals with the hippocampal amyloid-b deposition, TBS-T soluble Ab levels and high-molecular weight Ab aggregate
levels to gain a better understanding of the possible involvement of Ab in neurochemical and behavioral changes, cognitive
decline and neuropathological features in AbPP-PS1 transgenic mice. Our results show that at 8 months of age AbPPswe-
PS1dE9 mice display behavioral and cognitive changes compared to age-matched wild-type mice, as determined in the
open field and the (reverse) Morris water maze. However, there were no variations in hippocampal metabolite levels at this
age. AbPP-PS1 mice at 12 months of age display more severe behavioral and cognitive impairment, which coincided with
alterations in hippocampal metabolite levels that suggest reduced neuronal integrity. Furthermore, correlation analyses
suggest a possible role of Ab in inflammatory processes, synaptic dysfunction and impaired neurogenesis.
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Introduction
The cause of Alzheimer’s disease (AD) is still largely unknown
despite many years of extensive research. Since AD is character-
ized by the presence of neurofibrillary tangles and amyloid-b (Ab)
containing aggregates, it has been suggested that the Ab peptide is
a major contributor to the neurodegenerative processes in AD
[1,2]. The Ab peptide is derived through the proteolytic cleavage
of the amyloid-b precursor protein (AbPP) by the b- and c-
secretases, BACE and Presenilin (PS), and it accumulates in the
brain as neuritic plaques or as vascular wall deposits that may
cause cerebral amyloid angiopathy (CAA) [3,4]. In recent years,
research focus has shifted from the insoluble Ab plaques to the
soluble oligomeric forms of Ab as potential culprits of AD. Several
lines of evidence have indicated that soluble oligomers of Ab may
be responsible for synaptic dysfunction and cognitive impairment
in AD patients and transgenic animal models [5,6].
Besides Ab, several other potential causal mechanisms have
been proposed since the discovery of AD. Large epidemiological
studies have revealed that many risk factors for AD are vascular-
related, causing chronic cerebral hypoperfusion and cerebrovas-
cular pathology [7–11], suggesting that vascular disorders may
play an important role in the onset of AD. Another process that
has been implicated in the onset and development of AD is
chronic neuroinflammation [12–14]. Activated astrocytes and
microglia are found in abundance near Ab plaques and neurons at
risk in AD brains, producing several proinflammatory signal
molecules, including cytokines, growth factors, complement
molecules, and adhesion molecules [15,16]. Furthermore, several
studies have shown that activated microglia can suppress
hippocampal neurogenesis [17–19], thereby contributing to
cognitive dysfunction in aging and AD.
Rather than one sole mechanism, it is much more likely that AD
is a multifactorial disease, caused by a combination of these
factors, compromising the functional integrity of the brain. One
method of determining the functional integrity of the brain, or
specific brain regions, is to examine their metabolism by using
proton magnetic resonance spectroscopy (1H MRS). 1H MRS
allows the non-invasive in vivo analysis of certain neurometabolites
that indicate biochemical changes in the brain, which are thought
to be related to the pathological processes at the molecular or
cellular level [20,21]. Altered metabolic profiles, detected by 1H
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MRS, have been reported in patients with AD [22,23]. The most
consistent findings in AD patients are a reduction of the metabolite
N-acetylaspartate (NAA) and an elevation of the metabolite myo-
Inositol (mI) in several brain regions including the hippocampus
[20,24,25]. NAA is considered to be a marker of neuronal
viability, and a reduction of NAA is commonly interpreted as a
result of neuronal dysfunction or neuronal loss [26]. An elevation
of mI has been associated with inflammatory processes, since mI is
a putative marker for microglia and astrogliosis [27]. Furthermore,
disturbances of several other metabolites have been found in AD
patients, although the reports are inconsistent. Some studies
identified elevated choline-containing compounds (tCho) and
creatine (Cre) in AD patients [28–30], whereas others did not
[24,31].
Similar to AD patients, the most consistent finding in transgenic
animal models is a reduction of NAA, although this was found to
occur at different ages in different transgenic species apparently
depending on the interplay of mouse strain, transgene and disease
progression [32]. Furthermore, conflicting results have been
reported for several other metabolite levels, including mI, taurine
(Tau) and glutamate (Glu), even within the same transgenic animal
model [33]. Since 1H MRS has great potential for the early
diagnosis of AD, monitoring disease progression and evaluating
the efficacy of potential therapeutic agents, it is important to
characterize the alterations in neurometabolites in several
transgenic animals models of AD.
The present longitudinal study set out to characterize the
neurochemical profile of the hippocampus, measured by 1H MRS,
in the brains of AbPPswe-PS1dE9 and wild-type mice at 8 and 12
months of age. Furthermore, we wanted to determine whether
alterations in hippocampal metabolite levels coincided with
behavioral changes, cognitive decline and neuropathological
features, to gain a better understanding of the underlying
neurodegenerative processes. Moreover, the extracellular amy-
loid-b plaque load, TBS-T soluble Ab levels and high-molecular
weight Ab aggregate levels were determined in the brains of the
12-month-old AbPP-PS1 mice used in the present study [34]. We
performed correlation analyses with these Ab measures, to gain a
better understanding of the possible involvement of Ab in the
neurochemical and behavioral changes, cognitive decline and
neuropathological features in the AbPP-PS1 transgenic mice.
Providing well characterized AD animal models and better
understanding of the underlying pathological processes in AD is
required for the development and evaluation of potential
therapeutic targets.
Animals, Materials and Methods
Ethics Statement, Animals and Housing Conditions
The experiments were performed according to Dutch federal
regulations for animal protection and were approved by Veteri-
nary Authority of the Radboud University Nijmegen Medical
Centre (Permit Number: RU-DEC2008-126). All efforts were
made to minimize suffering of the animals.
The AbPPswe-PS1dE9 founders were obtained from Johns
Hopkins University, Baltimore, MD, USA (D. Borchelt and J.
Jankowsky, Dept. of Pathology) and a colony was established at the
Radboud University Nijmegen Medical Centre, the Netherlands.
In short, mice were created by co-injection of chimeric mouse/
human AbPPswe (mouse AbPP695 harboring a human Ab
domain and mutations K595N and M596L linked to Swedish
familial AD pedigrees) and human PS1dE9 (deletion of exon 9)
vectors controlled by independent mouse prion protein promoter
elements. The two transfected genes co-integrate and co-segregate
as a single locus [35,36]. This line (line 85) was originally
maintained on a hybrid background by backcrossing to C3HeJ6
C57BL6/J F1 mice (so-called pseudo F2 stage). For the present
work, the breeder mice were backcrossed to C57BL6/J for 9
generations to obtain mice for the current study. Throughout the
experiment animals were housed in groups of 2–3 mice per cage in
a controlled environment, homogenously illuminated by normal
fluorescent room light at 60 lux, with room temperature at 21uC,
and an artificial 12:12 h light:dark cycle (lights on at 7 a.m.). Food
and water were available ad libitum.
Male transgenic AbPP-PS1 mice and their wild-type littermates
underwent behavioral testing and MRI measurements at 8 months
of age, and again at 12 months of age. In total 25 mice were used:
at 8 months of age, 15 wild-type and 10 AbPP-PS1 mice, and at 12
months of age, 9 wild-type and 7 AbPP-PS1 mice. Due to some
technical problems during the experiments, not all mice could be
used for the statistical analyses for each measure. For example,
some mice were excluded from further analyses of the 1H MRS
data, since the spectra obtained did not meet the inclusion criteria.
The body weights of the mice were determined one day before the
start of the behavioral tests, and again on the day of the MRI
measurements.
Behavioral Analyses
Behavioral testing was performed in the following order: First
open field, followed by Morris water maze (MWM), and finally the
reversal MWM (rMWM). All testing sessions were performed
during the light phase (between 9 a.m. and 5 p.m.) and were
recorded for computer-assisted analysis using Noldus Ethovision
3.1 software (Noldus Information Technology B.V., Wageningen,
the Netherlands). All behavioral testing was performed in the same
room, homogenously illuminated by normal fluorescent room light
at 60 lux.
Open field. To analyze explorative and anxiety-related
behavior, mice were placed individually in the center of a square
open field (50650650 cm) with white Plexiglas walls, and were
observed for 30 minutes. The duration (seconds) of walking, wall
leaning, rearing, sitting and grooming were scored and later
analyzed in three blocks of 10 minutes. These open field
parameters were defined as described previously [37,38]. In
addition, total walking distance, mean velocity, and the time spent
in the corners respectively the center of the open field were
obtained from the recorded sessions. The center of the open field
was defined as a square measuring 20620 cm, and the corners of
the open field were defined as the sum of all four 10610 cm
squared corners.
Morris water maze (MWM). To investigate spatial learning
abilities, mice were tested in the Morris water maze (MWM). In
short, mice were placed in a pool (104 cm diameter) filled with
water (21–22uC; made opaque by the addition of milk powder) at
different starting positions and trained to find a submerged
platform by using distant visual cues in the room. These spatial
cues were present on the four walls of the test room at a distance of
0.5 meter. The 8 cm diameter round platform was submerged
1 cm below the water surface and placed in the middle of the
northeast (NE) quadrant at a distance of 26 cm from the wall.
During all trials the researcher was present and always located at
the same location in the room (close to the SW quadrant).
Acquisition (spatial learning): Mice were trained to find the
location of the submerged escape platform in 4 acquisition trials
(maximal swimming time 120 s; 30 s on the platform; inter-trial
interval 60 min) per day during 4 consecutive days. The latency
time (s) to find the hidden platform was scored. Starting positions
during the 4 trails/day were: S, N, E, W. After the 2 min swim the
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mice were placed back in their home cage, and a paper towel was
available inside the cage for additional drying.
Probe (spatial memory): All mice performed a single probe trial
60 min after the last trial on day 4, in which the platform was
removed from the swimming pool. Mice were allowed to swim for
60 s and the time spent swimming and searching in the NE
quadrant (where the platform had been located), total swimming
distance, mean velocity and total number of platform crossings (at
the former platform location) were recorded.
Reverse morris water maze (rMWM). Four days after the
standard MWM probe trial, a simplified reversal MWM [38] was
performed in which the platform location was changed to the
southwest (SW) quadrant. In this procedure, earlier platform
location need to be encoded in the long-term memory. Memory
retrieval needs to be selective for the most recently learned
location, introducing an episodic like component in the spatial
memory task [39]. Acquisition and probe sessions were performed
similar to the standard MWM sessions, except that starting
positions were E, W, S, and N, the target quadrant was SW, and
training lasted only 2 days (4 trials/day).
Magnetic Resonances Spectroscopy (MRS)
MR measurements were performed on a 7T/300 mm horizon-
tal-bore MR spectrometer interfaced to a ClinScan console
(Bruker Biospin, Ettlingen, Germany). An integrated circular
polarized transmit 1H volume coil (200 mm/154 mm outer/inner
diameter) combined with a circular polarized receive 1H surface
coil was used for signal reception. During the experiments, mice
were anesthetized with 2% isoflurane (Abott, Cham, Switzerland)
in a mixture of N2O and oxygen (1:2) through a nose cone. Mice
were placed in a stereotactic holder to prevent unwanted
movement during the scanning. Body temperature was maintained
at a physiological level with heated airflow and was monitored
with a rectal optical temperature probe. Respiration of the animal
was monitored using a pneumatic cushion respiratory monitoring
system (Small Animal Instruments Inc, NY, USA). Multislice turbo
spin echo images in the coronal, transversal and longitudinal
orientation were acquired to visualize the anatomy and the
morphology of the mouse brain structures. Imaging parameters
were: FOV=25625 mm, matrix size = 2566256, slice thick-
ness = 0.5 mm, TE=46 ms, and TR=3500 ms.
Metabolite concentrations in the hippocampus were determined
using proton magnetic resonance spectroscopy (1H MRS) with a
single voxel technique. The spectroscopic volume of interest (VOI)
of 1.061.061.6 mm was positioned in the hippocampus (Figure 1),
according to the mouse brain atlas of Franklin and Paxinos [40].
Water-suppressed 1H-MRS spectra were acquired with the
stimulated echo acquisition mode (STEAM) sequence with
experiment parameters: TR=1500 ms, TE= 13 ms, and 1024
signal averages. Water suppression was performed with variable
pulse power and optimized relaxation delays (VAPOR). For each
1H MRS spectrum, a water reference spectrum was acquired
without water suppression with experiment parameters:
TR=1500 ms, TE= 13 ms, and 32 signal averages. Total
acquisition time for 1H MRS was 27 min per animal.
Quantification of the metabolite concentration was performed
using a the Linear Combination (LC) model software package
(LCModelTM, S. Provencher, Oakville, Canada). The quantifica-
tion algorithm of LCModelTM applies linear combinations of
model spectra to calculate the best fit of the experimental
spectrum. The model spectra (dataset of prior knowledge) are
calibrated to match the magnetic field strength, sequence type and
sequence parameters used for data acquisition. The final analysis is
performed in the frequency domain with raw data (free induction
decay (FID)) as the input. The unsuppressed water spectrum was
used to estimate the absolute concentration of the metabolites, of
which simulated model spectra, generated by NMRSIMTM
(Bruker Biospin, Ettlingen, Germany) were taken into the analysis.
The criteria to select reliable metabolite concentrations were
based on the Crame´r-Rao lower bounds (CRLB), which are
estimates of the S.D. of the fit for each metabolite [41] and are also
determined by LCModelTM. Only fit results with a CRLB #20%
were included in the analysis. Concentrations with CRLB.20%
were classified as not accurately detectable. Based on these criteria,
2 wild-type and 2 AbPP-PS1 mice at 8 months of age, and 2 wild-
type and 3 AbPP-PS1 mice at 12 months of age were excluded
from further analyses, since they displayed fit results with
CRLB.20%. Only metabolite fits that had a CRLB #20% in
more than 80% of the spectra were included, and individual
concentrations with corresponding CRLB.20% were not taken
into account.
Seven metabolites fulfilled the criteria: choline+glyceropho-
sphocholine+phosphocholine (tCho), creatine+phosphocreatine
(tCre), glutamate (Glu), glutamine+glutamate (Glx), myo-Inositol+-
glycine (mI+Gly), N-acetylaspartate (NAA) and taurine (Tau).
Although the exact function of these metabolites are not fully
known, NAA is considered to be a marker of neuronal viability,
tCre is involved in energy metabolism, mI is a putative marker for
microglia and astrogliosis, and tCho is required for the synthesis of
the neurotransmitter acetylcholine, and of phosphatidylcholine, a
major constituent of membranes, and is therefore associated with
membrane turnover [27].
Immunohistochemistry
Directly following the MR measurements at 12 months of age,
mice were sacrificed by cervical dislocation, and subsequently
brains were removed from the skull after decapitation. Brains were
weighed and cut mid sagittal for immunohistochemistry and
biochemistry. One hemisphere was snap frozen in liquid nitrogen
and then stored at 280uC, before further biochemical processing.
The other hemisphere was immersion fixated in 4% paraformal-
dehyde for 24 hours, and subsequently stored in 0.1 M phosphate
buffered saline (PBS, pH=7.3) with 1% sodium azide at 4uC.
Before cutting, the brain tissue was cryoprotected by immersion in
30% sucrose in 0.1 M phosphate buffer (PB, pH=7.3). Six series
of 40 mm coronal sections were cut through the brain using a
sliding microtome (Microm HM 440 E, Walldorf, Germany). For
every staining, one complete series with 240 mm distance between
the sections was used. Immunohistochemistry was performed using
standard free-floating labeling procedures [42], and was carried
out on a shaker table at room temperature.
Presynaptic boutons were visualized with anti-synaptophysin
antibody (1:20,000; monoclonal rabbit anti-synaptophysin clone
EP1098Y, Abcam Inc., Cambridge, UK) using one subseries of
brain sections per animal. Synaptophysin is localized in small
synaptic vesicles of the presynaptic terminal and functions in the
regulation of exocytosis [43]. Donkey anti-rabbit biotin 1:1500
(Jackson ImmunoResearch, West Grove, PA, USA) was used as
secondary antibody.
Immature neurons were visualized with anti-doublecortin
antibody (1:3000; polyclonal goat anti-doublecortin (C18): sc-
8066, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
using one subseries of brain sections per animal. Doublecortin is a
microtubule-associated protein that is exclusively found in somata
and processes of migrating and differentiating neurons [44,45].
Donkey-goat biotin 1:1500 (Jackson ImmunoResearch, West
Grove, PA, USA) was used as secondary antibody.
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Quantification
Quantification of presynaptic boutons and doublecortin-positive
immature neurons was performed using a Zeiss Axioskop
microscope, equipped with hardware and software from Micro-
brightfield (Williston, VT, USA). Appropriate sections were
digitized and photomicrographed using a computer-assisted
analysis system, Stereo Investigator (Microbrightfield). Brain
regions were based on the mouse brain atlas of Franklin and
Paxinos [40]. All measurements were performed double blind by
two independent raters, and measurements were averaged to
obtain a single value per animal for every region of interest.
Quantification of synaptophysin-immunoreactive
presynaptic boutons. To determine the amount of synapto-
physin-immunoreactive presynaptic boutons (SIPBs) in the hippo-
campus and cortical regions, appropriate sections were digitized
and photomicrographed using an 1006 oil immersion objective.
SIPBs were analyzed in the hippocampal regions stratum
radiatum (SR) of the cornu ammonis (CA)1 area, stratum lucidum
(SL) of the CA3 area, inner molecular layer (IML) and outer
molecular layer (OML) of the dentate gyrus (DG), and in the
cortical regions prelimbic area (PLA) and anterior cingulate gyrus
(ACg). These regions were chosen because of their large amyloid
load in AD patients and transgenic mouse models for AD and their
importance in learning and memory [46,47]. The ACg was
quantified at level +1.10 up to +0.86 anterior to bregma using one
appropriate section per animal, the PLA was quantified at +1.98
up to +1.78 anterior to bregma using one appropriate section per
animal, and hippocampal regions were quantified at 22.18 up to
22.46 posterior to bregma using one appropriate section per
animal. For every region of interest, two square boxed were placed
within the borders of the intended area using an 2.5 or 56
objective and images were taken using an 1006 oil immersion
objective (Figure 2). Images were further processed using ImageJ
software (U.S. National Institutes of Health, Bethesda, MD, USA)
for the quantification of the amount of SIPBs. All settings were
kept identical for all analyses and background levels were
equalized using a threshold. Shading correction was performed
before measurement to correct for irregularities in illumination in
the microscopic field. A differential contrast enhancement filter
was applied to selectively enhance weak differences in contrast. To
eliminate noise signal and to differentiate between possible
artifacts and specific SIPBs, particles were classified based on
size. Particles ranging between 0.1–4.5 mm2 were considered to be
normal sized SIPBs [48,49], and were included for statistical
analyses. Particles smaller than 0.1 mm2 and larger than 4.5 mm2
were excluded for analyses. The amount of SIPBs/mm2 was
defined as the number of particles divided by the total area
analyzed.
Quantification of doublecortin-positive cells. For the
assessment of immature neurons in the hippocampus as a measure
for neurogenesis (Figure 3), three alternating sections per animal
(at 22.18. 22.46 and 22.70 posterior to bregma) were digitized
and contours were drawn along the borders of the hippocampus
using an 56 objective using Stereo Investigator software.
Doublecortin-positive (Dcx+) cells were counted with an 206
objective, and the values of the three alternating sections were
averaged to obtain a single value per animal.
Amyloid-b Measures
The extracellular Ab load, soluble Ab levels and insoluble high-
molecular weight Ab aggregate levels were determined in the
brains of the 12-month-old AbPP-PS1 mice, as has been described
elsewhere [34].
In short, Ab deposits were visualized using WO-2 antibody
(1:20,000, mouse anti-human Ab4–10, a kind gift of K. Beyreuther,
University of Heidelberg, Germany) using one subseries of brain
sections per animal. Donkey anti-mouse biotin (1:1500, Jackson
ImmunoResearch was used as secondary antibody. Extracellular
Ab plaque load was quantified in the hippocampus, prelimbic area
(PLA) and anterior cingulate gyrus (ACg) with a computer-assisted
analysis system (Stereo Investigator, Microbrightfield) using
Cavalieri’s probe (Figure 4). The Ab plaque load was defined as
the percentage of area covered by Ab.
For biochemical Ab analyses, frozen hemibrains were homog-
enized in Tris buffered saline with 1% Triton X-100 (TBS-T) plus
protease inhibitor cocktail (Roche Applied Science, Mannheim,
Germany) and centrifuged at 16,000 g for 30 min at 4uC.The
supernatant, enriched with oligomeric Ab, was collected and
stored at 280uC. The pellet, containing mainly highly aggregated
Ab, was resuspended in guanidine chloride buffer and extracted
for 4 hours. The TBS-T and guanidine HCl extracts were
analyzed for human Ab40 and Ab42 (KHB3442 and KH3482,
Invitrogen, Karlsruhe, Germany) according to the manufacturers
protocol. Results were normalized to the protein concentration of
Figure 1. Localization of the spectroscopic volume of 1.061.061.6 mm placed in the hippocampus.
doi:10.1371/journal.pone.0063643.g001
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the sample (Bio-Rad Protein Assay, Bio-Rad Laboratories,
Munich, Germany).
Statistical Analysis
Data are expressed as mean6SEM and were analyzed with
SPSS for windows 16.0 software (SPSS Inc. Chicago, IL, USA).
The repeated measures ANOVA was used for the open field
parameters (with the repeated measure: time) and the acquisition
phase of the MWM and rMWM (with the repeated measure: trial
block), followed by a Bonferroni post hoc to analyze possible
interactions between time/trial block and genotype. If interactions
between time/trial block and genotype (between-group-factors)
were present, the data were split for the concerning factor and
thereafter analyzed again with the repeated measures ANOVA.
Multivariate ANOVA’s were conducted with between group
factor: genotype, to analyze possible differences between wild-type
and AbPP-PS1 mice in the probe trials of the MWM and rMWM,
the body weight, brain weight, metabolite concentrations, and the
amount of SIPBs and immature neurons. Aging effects in the
AbPP-PS1 mice are represented as relative values compared to the
wild-type mice (set as 100%) of the corresponding age-group, and
were analyzed with between group factor: age. Correlation
analyses with the Ab measures were performed using bivariate
Pearson’s correlation method. For clarity reasons, F-values are not
displayed. Statistical significance was set at p,0.05.
Results
Body and Brain Weight
All mice were weighed one day before starting the behavioral
test battery and again on the day of the MR measurements. Since
body weights within the groups did not change significantly
between those two time points, the mean weight was used for
further statistical analyses. Both at 8 months and 12 months of age,
AbPP-PS1 mice had a tendency towards a higher body weight
than wild-type mice, but it did not reach statistical significance. At
8 months of age, overall mean body weight of the AbPP-PS1 mice
was 29.7960.65 g compared to 28.2460.42 g of the wild-type
mice (p=0.051). At 12 months of age, overall mean body weight of
the AbPP-PS1 mice was 33.0361.23 g compared to 30.1360.76 g
of the wild-type mice (p = 0.060).
Figure 2. Representative image of synaptophysin-immunoreactive presynaptic boutons (SIPBs) in the hippocampus of a 12-month-
old wild-type mouse. A: In the hippocampus SIPBs were analyzed in the inner (yellow) and outer (red) molecular layer of the dentate gyrus,
stratum radiatum (SR) of the CA1 area (blue), and stratum lucidum (SL) of the CA3 area (green). Scale bar = 200 mm. B: SIPBs were quantified with an
1006 objective using image analysis from digitized photomicrographs of the synaptophysin-immunoreactivity. Scale bar = 10 mm.
doi:10.1371/journal.pone.0063643.g002
Figure 3. Representative image of doublecortin-positive (Dcx+)
cells in the hippocampus of a 12-month-old wild-type mouse.
A: Image taken using an 106 objective. Scale bar = 100 mm. B: Image
taken with an 406 objective. Scale bar = 50 mm.
doi:10.1371/journal.pone.0063643.g003
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Both relative and absolute brain weights were not affected by
genotype (p = 0.812 and p=0.165 respectively). Overall mean
brain weight of the AbPP-PS1animals was 0.4960.01 g, which
was 1.4660.08% of their total body weight. Overall mean brain
weight of the wild-type mice was 0.4560.02 g, which was
1.4960.07% of their total body weight.
Behavioral Analyses
Open field. During the 30 min observation at 8 months of
age, both in wild-type and AbPP-PS1 mice the time spent walking
(Figure 5A; p,0.001) and wall leaning (Figure 5I; p=0.038)
decreased, as well as the distance traveled (Figure 5G; p,0.001)
and mean velocity (p,0.001). Accordingly, the time spent sitting
(Figure 5C; p,0.001) increased during the 30 min observation
period. The time spent rearing (Figure 5E; p=0.632) and
grooming (Figure 5K; p=0.263), as well as the time spent in the
center (Figure 5 M; p=0.673) and in the corners (Figure 5O;
p=0.106) of the open field remained constant over time.
8-month-old AbPP-PS1 mice were more active in the open field
than wild-type mice:
AbPP-PS1 mice traveled a longer distance (Figure 5G;
p=0.048) and had a higher mean walking speed than wild-type
mice (p=0.043; wild-type 5.660.3 cm/s, AbPP-PS1 6.960.5 cm/
s), although the time spent walking and sitting did not differ from
the wild-type animals (Figure 5A; p=0.293 and Figure 5C;
p=0.964 respectively). AbPP-PS1 mice also spent less time rearing
than wild-type mice (Figure 5E; p=0.043). No differences were
observed between the genotypes in the time spent wall leaning
(Figure 5I; p=0.642) and grooming (Figure 5K; p=0.259), and in
the time spent in the center (Figure 5 M; p=0.274) and corners of
the open field (Figure 5O; p=0.189).
Like at 8 months of age, the time spent walking (Figure 5B;
p=0.001), the distance traveled (Figure 5H; p=0.001), and mean
velocity (p=0.001) decreased over time in both wild-type and
AbPP-PS1 mice at 12 months of age. In contrast, the time spent
grooming increased at this age during the 30 min open field
(Figure 5L; p=0.009), whereas the time spent sitting (Figure 5D;
p=0.104) and wall leaning (Figure 5J; p=0.443) remained
constant throughout the observation period. Again, the time spent
rearing (Figure 5F; p=0.866), as well as the time spent in the
center (Figure 5N; p=0.389) and the corners (Figure 5P; p=0.465)
of the open field did not change over time.
Compared to wild-type mice, 12-month-old AbPP-PS1 mice
spent more time wall leaning (Figure 5J; p=0.041), and slightly less
time walking (Figure 5B; p=0.058), although the distance traveled
(Figure 5H; p=0.859) and mean velocity of the AbPP-PS1 mice
did not differ from the wild-type animals (p=0.886; wild-type
4.760.3 cm/s, AbPP-PS1 4.760.5 cm/s). Furthermore, AbPP-
PS1 mice spent more time in the corners (Figure 5P; p=0.001),
and less time in the center of the open field (Figure 5N; p=0.021)
as compared to wild-type mice. At this age, no differences were
observed between the genotypes in the time spent sitting
(Figure 5D; p=0.349), rearing (Figure 5F; p=0.359) and
grooming (Figure 5L; p=0.564).
Aging effects in the AbPP-PS1 mice were analyzed as relative
values compared to the wild-type mice (set as 100%) of the
corresponding age. With age, the time that AbPP-PS1 mice spent
walking decreased, from 105.7%63.8 at 8 months of age to
79.5%67.1 at 12 months of age (p=0.016), indicating decreased
activity as disease progresses or decreased restlessness due to
habituation to the open field. However, the traveled distance and
mean velocity did not change with age (p=0.105) as compared to
age-matched wild-type animals (data not shown). Over time,
AbPP-PS1 mice also spent more time in the corners of the open
field (p=0.018). Time spent in the corners of the open field
increased from 115.7%67.1 at 8 months of age to 169.3%615.1
at 12 months of age, indicating increased anxiety-related behavior
as disease progresses. The time spent sitting (p=0.786), rearing
(p=0.481), grooming (p=0.086), wall leaning (p=0.087) and the
time spent in the center of the open field (p=0.116) did not change
between 8 and 12 months of age (data not shown).
Altogether, these data show increased activity but decreased
active exploration (rearing) in 8-month-old AbPP-PS1 mice
compared to wild-type mice. This increased activity and decreased
rearing disappear at 12 months of age, due to habituation to the
open field and/or the older age of the animals. Instead, 12-month-
old AbPP-PS1 mice show increased anxiety-related behavior
compared to wild-type mice, as indicated by the increased time
spent in the corners and decreased time spent in the center of the
open field, and increased time spent wall leaning, which is a type
of exploration but with an anxiety-related behavioral component
[38,50].
Morris water maze (MWM). Both AbPP-PS1and wild-type
mice showed a decrease in escape latency during training at 8
months of age (Figure 6A; p,0.001). However, wild-type mice
Figure 4. Representative images of the amyloid-b plaque load in the brain of a 12-month-old AbPP-PS1 mouse. A: The Ab plaque load
was quantified in the prelimbic area at level +1.98 up to +1.78 anterior to bregma, B: in the anterior cingulate gyrus at level +1.10 up to +0.86 anterior
to bregma, and C: in the dentate gyrus (DG), CA1 and CA3 areas of the hippocampus at level 22.18 up to 22.46 posterior to bregma, using one
appropriate section per animal. Images were taken using a 2.56 objective. Scale bar = 500 mm.
doi:10.1371/journal.pone.0063643.g004
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learned to find the location of the hidden platform faster than the
AbPP-PS1 mice, indicated by a significant time*genotype inter-
action (p=0.009). Overall escape latencies tended to differ
between wild-type and AbPP-PS1 (p=0.060) at 8 months of age,
although it did not reach statistical significance. Especially on day
2 of the acquisition phase, AbPP-PS1 mice showed higher escape
latencies than wild-type mice, suggesting that spatial learning
might be mildly affected at this age.
During the probe trial at 8 months of age, no differences were
found between wild-type and AbPP-PS1 mice in the time spent in
the platform quadrant (NE) (Figure 6C; p=0.266). However, only
wild-type mice deviated from 25% chance performance level,
Figure 5. Open field behavior in AbPP-PS1 and wild-type mice at 8 and 12 months of age. Different open field parameters were measured
within a 30 min period, and analyzed in three 10 min trial blocks. A and B: AbPP-PS1 mice (n = 5) did not differ from wild-type mice (n = 8) at 8
months of age (A), but spent slightly less time walking than wild-type mice at 12 months of age,# trend p=0.058 (B). C and D: The duration of sitting
was similar among wild-type and AbPP-PS1 mice at 8 (C) and at 12 months of age (D). E and F: AbPP-PS1 mice spent less time rearing than wild-type
mice at 8 months of age, *p,0.05 (E), but did not differ from wild-type mice at 12 months of age (F). G and H: AbPP-PS1 mice traveled a longer
distance than wild-type mice at 8 months of age, *p,0.05 (G), but did not differ from wild-type mice at 12 months of age (H). I and J: The duration of
wall leaning was similar among wild-type and AbPP-PS1 mice at 8 months of age (I), but was increased in AbPP-PS1 mice at 12 months of age,
*p,0.05 (J). K and L: Both at 8 (K) and 12 months of age (L), the time spent grooming was similar among wild-type and AbPP-PS1 mice. M and N:
AbPP-PS1 mice did not differ from wild-type mice at 8 months of age (M), but spent less time in the center of the open field than wild-type mice at 12
months of age, *p,0.05 (N). O and P: AbPP-PS1 mice (n = 7) spent more time in the corners of the open field than wild-type animals (n = 9) at 12
months of age, *p,0.05 (P), but did not differ from wild-type at 8 months of age (O).
doi:10.1371/journal.pone.0063643.g005
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Figure 6. Morris water maze learning and memory in 8- and 12-month-old wild-type and AbPP-PS1mice. Spatial learning was measured
in a 4-day acquisition phase, by determining the latency to find a hidden platform in the NE quadrant. Spatial memory was tested in the probe phase
in which the percentage of time spent in the target NE quadrant was measured and the total number of platform crossings (where formerly the
platform had been located). A: Both 8-month-old wild-type (n = 14) and AbPP-PS1 mice (n = 10) showed a decrease in latency during training. Overall
latencies tended to be higher in AbPP-PS1 mice, although it did not reach statistical significance, # trend p= 0.060. B: During the probe trial, the 8-
month-old AbPP-PS1 mice traveled a slightly longer distance than wild-type animals, although it did not reach statistical significance, # trend
p= 0.056. C: No differences were observed between the 8-month-old mice in the percentage of time spent in the target NE quadrant, although only
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suggesting that only wild-type mice showed good memorization of
the platform quadrant. Furthermore, AbPP-PS1 mice crossed the
exact platform location less often than wild-type mice (Figure 6D;
p=0.019), reflecting impaired spatial memory for the exact
platform location. No significant differences were found between
the genotypes in the total distance moved (Figure 6B; p=0.056)
and mean swim velocity (p=0.078; wild-type 17.561.2 cm/s,
AbPP-PS1 20.460.5 cm/s) during the probe trial, although the
AbPP-PS1 mice tended to be slightly more active than the wild-
type animals.
Both wild-type and AbPP-PS1 animals learned to find the
platform during acquisition at 12 months of age (Figure 6E), as
indicated by a decrease in latency over trials (p,0.001). Escape
latencies did not differ between the wild-type and AbPP-PS1 mice
(p=0.525), indicating that spatial learning was no longer affected
by genotype at this age, most likely due to the repetition of this
task.
AbPP-PS1 mice spent less time in the NE target quadrant
compared to their wild-type littermates at 12 months of age
(Figure 6G; p=0.013), although both groups performed above
25% chance level, indicating memorization of the platform
quadrant. No differences were found between the genotypes in
the frequency of platform crossings (Figure 6H; p=0.131), the
total distance moved (Figure 6F; p=0.221) and mean swim
velocity (p=0.232; wild-type 17.260.8 cm/s, AbPP-PS1
18.760.8 cm/s) during the probe trial.
Aging effects in the AbPP-PS1 mice were analyzed as relative
values compared to the wild-type mice (set as 100%) of the
corresponding age. Escape latencies during training in the MWM
decreased with age (p=0.001), such that the average escape
latency of all 4 days was 128.2%66.5 at 8 months of age relative
to age-matched wild-type animals and 88.2%67.2 at 12 months of
age, indicating that 12-month-old AbPP-PS1 mice found the
location of the hidden platform faster than 8-month-old AbPP-PS1
mice, most likely due to habituation to and repetition of the MWM
task at 12 months of age. The time spent in target NE quadrant
(p = 0.380), the number of platform crossings (p = 0.167), the
distance moved (p=0.121), and mean swim velocity (p=0.173) did
not change between 8 and 12 months of age (data not shown).
Reverse Morris water maze (rMWM). Both wild-type and
AbPP-PS1 animals learned to find the new SW platform location
during acquisition at 8 months of age (Figure 7A), as indicated by a
decrease in latency over trials (p=0.046). Overall escape latencies
did not differ between wild-type and AbPP-PS1 (p=0.693).
No differences were found between wild-type and AbPP-PS1 in
the time spent in the SW quadrant during the probe trial at 8
months of age (Figure 7C; p=0.271). However, only wild-type
mice deviated from 25% chance performance level, suggesting
that only wild-type mice showed good memorization of the new
platform quadrant. No differences were found between the
genotypes in the number of platform crossings (Figure 7D;
p=0.187), total distance moved (Figure 7B; p=0.129) and mean
swim velocity (p=0.111; wild-type 17.661.0 cm/s, AbPP-PS1
19.860.7 cm/s) during the probe trial.
At 12 months of age, the wild-type animals showed a significant
decrease in escape latency over time in the acquisition phase
(Figure 7E; p=0.001), indicating spatial learning. In contrast,
escape latencies did not change over time in the AbPP-PS1 mice at
12 months of age (p=0.649), due to unexpected low latencies at
the initial trials. In spite of that, there was no difference in average
escape latencies between AbPP-PS1 and wild-type animals
(p=0.134).
During the probe trial at 12 months of age, AbPP-PS1 mice
tended to spent less time in the target SW quadrant than wild-type
mice (Figure 7G; p=0.066), although it did not reach statistical
significance. Furthermore, only wild-type mice deviated from 25%
chance performance level, suggesting that only wild-type mice
showed good memorization of the new platform quadrant. AbPP-
PS1 mice also crossed the former platform location significantly
less often than wild-type animals (Figure 7H; p=0.029), reflecting
impaired spatial memory as well. No significant differences were
found between the genotypes in the total distance moved
(Figure 7F; p=0.066) and mean swim velocity (p=0.066; wild-
type 17.161.0 cm/s, AbPP-PS1 19.960.9 cm/s), although the
AbPP-PS1 mice tended to be slightly more active than the wild-
type animals.
Aging effects in the AbPP-PS1 mice were analyzed as relative
values compared to the wild-type mice (set as 100%) of the
corresponding age. Escape latencies during training in the rMWM
did not change with age and repetition of the rMWM test
(p=0.123).
During the probe trial, the swim distance increased with age
(p=0.049) from 111.4%63.7 at 8 months to 116.2%65.2 at 12
months, indicating hyperactivity as disease progresses. The time
spent in the SW target quadrant (p=0.165) and number of
platform crossings (p=0.456) did not change between 8 and 12
months of age (data not shown).
Magnetic Resonance Spectroscopy (MRS)
No differences were observed in the neurochemical profile of
the hippocampus of 8-month-old wild-type and AbPP-PS1 mice
(Figure 8C). Wild-type and AbPP-PS1 mice had similar concen-
trations of choline-containing compounds (tCho; p=0.514),
creatine and phosphocreatine (tCre; p=0.712), glutamate (Glu;
p=0.785), glutamine and glutamate (Glx; p=0.181), myo-Inositol
and glycine (mI+Gly; p=0.272), N-acetylaspartate (NAA;
p=0.456), and taurine (Tau; p=0.245).
At 12 months of age, AbPP-PS1 mice had significantly lower
concentrations of NAA (p=0.012) than wild-type mice, indicating
decreased neuronal health and/or increased neurodegeneration
(Figure 8D). No differences were observed between wild-type and
AbPP-PS1 mice in the levels of tCho (p=0.123), tCre (p=0.986),
Glu (p=0.162), Glx (p=0.807), mI+Gly (p=0.082) and Tau
(p=0.804).
Aging effects in the AbPP-PS1 mice were analyzed as relative
values compared to the wild-type mice (set as 100%) of the
corresponding age. With age, the concentration of NAA decreased
from 94.7%66.0 at 8 months of age to 65.1%68.4 at 12 months
of age (p=0.017), indicating decreased hippocampal neuronal
viability as disease progresses.
Immunohistochemistry
At 12 months of age, there were no significant differences in the
amount of synaptophysin-immunoreactive presynaptic boutons
wild-type mice deviated from 25% chance performance level. D: 8-month-old AbPP-PS1 mice crossed the exact platform location less often than wild-
type mice, *p,0.05. E: Both 12-month-old wild-type (n = 9) and AbPP-PS1 mice (n = 7) showed a decrease in latency during training. Overall latencies
did not differ between the genotypes. F: During the probe trial, no differences were observed in the distance moved between 12-month-old wild-
type and AbPP-PS1 mice. G: 12-month-old AbPP-PS1 mice spent less time in the target NE quadrant, although both groups performed above 25%
chance level, *p,0.05. H: No differences were observed between the 12-month-old mice in the frequency of platform crossings.
doi:10.1371/journal.pone.0063643.g006
Cognition and Proton MRS in Aging APP/PS1 Mice
PLOS ONE | www.plosone.org 9 May 2013 | Volume 8 | Issue 5 | e63643
Figure 7. Reverse Morris water maze learning and memory in 8- and 12-month-old wild-type and AbPP-PS1 mice. Spatial learning with
an extra episodic memory component was measured in a 2-day acquisition phase, by determining the latency to find a hidden platform in the SW
quadrant. Spatial memory was tested in the probe phase in which the percentage of time spent in the target SW quadrant was measured and the
total number of platform crossings (where formerly the platform had been located). A: Both 8-month-old wild-type (n = 14) and AbPP-PS1 mice
(n = 10) showed a decrease in latency during training. Overall latencies did not differ between the genotypes. B: During the probe trial, the 8-month-
old wild-type and AbPP-PS1 mice traveled a similar distance. C: No differences were observed between the 8-month-old mice in the percentage of
time spent in the target SW quadrant, although only wild-type mice deviated from 25% chance performance level. D: No differences were observed
between the 8-month-old mice in the frequency of platform crossings E: Only 12-month-old wild-type mice (n = 9) showed a decrease in latency
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(SIPBs) between AbPP-PS1 and wild-type mice (Figure 9) in any of
the regions analyzed (p.0.10). Furthermore, no significant
differences were found in the amount of doublecortin-positive
(Dcx+) immature neurons between 12-month-old AbPP-PS1 and
wild-type mice (p=0.082; wild-type 9.261.5 Dcx+ cells, n = 6;
AbPP-PS1 5.560.3 Dcx+ cells, n = 4).
Amyloid-b Measures
Correlation analyses with the extracellular amyloid-b deposi-
tion, TBS-T soluble Ab levels and high-molecular weight Ab
aggregate levels found in the brains of 12-month-old AbPP-PS1
mice [34] were performed using bivariate Pearson’s correlation
method.
No significant interactions were found between any of the Ab
measures and the open field data (p.0.05), and the MWM and
rMWM acquisition and probe data (p.0.05).
A significant negative correlation was found between the Ab
plaque load in the hippocampus and the tCho levels measured
with 1H MRS (p=0.005; R=20.995). Furthermore, increased
mI+Gly levels significantly correlated with increased levels of the
high-molecular weight Ab40 (p=0.007; R= 0.993) and Ab42
(p=0.003; R= 0.997) aggregates.
A significant negative correlation was found between the TBS-T
soluble Ab42 levels and the amount of SIPBs in the PLA region
(p=0.040; R=20.895). In contrast, positive correlations were
found between the amount of SIPBs in the SR region of the
hippocampus and the levels of high-molecular weight Ab40
(p=0.009; R= 0.962) and Ab42 (p=0.027; R=0.920) aggregates.
However, these correlations between the amount of SIPBs and Ab
measures did no longer reach significance when Bonferroni’s
correction for multiple comparisons was applied (p.0.008).
Finally, we found a significant negative correlation between the
amount of immature neurons and the level of high-molecular
weight Ab40 (p=0.041; R=20.959) aggregates, suggesting
impaired neurogenesis with increasing levels of Ab40 aggregates.
Discussion
The present longitudinal study set out to characterize the
neurochemical profile of the hippocampus, measured by 1H MRS,
in the brains of AbPPSswe-PS1dE9 mice at 8 and 12 months of
age as compared to age-matched wild-type littermates. Further-
more, we wanted to determine whether alterations in hippocampal
metabolite levels coincided with behavioral changes, cognitive
decline and neuropathological features, to gain a better under-
standing of the underlying neurodegenerative processes. More-
over, we determined the extracellular amyloid-b load, TBS-T
soluble Ab levels and high-molecular weight Ab aggregate levels of
the 12-month-old AbPP-PS1 mice in our laboratory [34]. We
performed correlation analyses using bivariate Pearson’s correla-
tion method to gain a better understanding of the possible
involvement of Ab in neurochemical and behavioral changes,
cognitive decline and neuropathological features in AbPP-PS1
transgenic mice.
In agreement with previous results from our lab [38], 8-month-
old AbPP-PS1 mice already display behavioral changes in the
open field, such as increased locomotor activity and decreased
exploration. The increased activity is a specific characteristic of
many AbPP transgenic mice [51–54] and may be explained as a
result of elevated anxiety levels [53,55] or impaired habituation
learning [51,52]. In our view increased anxiety is most likely, since
the AbPP-PS1 mice also showed less rearing behavior (exploring
the environment) compared to age-matched wild-type mice.
Curiosity motivates mice to explore a novel environment, but this
exploratory drive is in conflict with fear of the unknown.
Moreover, 12-month-old AbPP-PS1 mice also showed increased
anxiety-related behavior, as indicated by the increased time spent
in the corners of the open field, increased time spent wall leaning,
and decreased time spent in the center of the open field (i.e.
anxious mice prefer the borders of the open field). Increased
anxiety and restlessness, as noticed as hyperactivity in several
AbPP transgenic mouse models, also occur in AD patients [56,57].
However, activity levels decreased between 8 and 12 months of
age both in AbPP-PS1 and wild-type mice, suggesting increased
familiarity with the open field even after 4 months.
In line with previous results from our lab, AbPP-PS1 mice also
showed impaired performance in the MWM and rMWM both at
8 and 12 months of age as compared to wild-type littermates [38],
which might suggest visuo-spatial learning and memory deficits.
Noteworthy are the relatively low escape latencies of both AbPP-
PS1 and wild-type mice during the initial trials of the rMWM
training at 8 months. Although 8-month-old wild-type mice
displayed good short-term spatial memory for the NE platform
location during the probe of the MWM, it appears that this
information might not have been sufficiently consolidated in the
long-term memory since they displayed more ‘‘random’’ search
during the initial rMWM trials (resulting in lower escape latencies)
than expected if animals had good long-term memory for the
former platform location. One possible explanation could be that
the MWM task as used in the current study was slightly too
difficult to optimally master within 4 days of training. For mice, a
MWM pool with a diameter of 120 cm and a platform of
10212 cm in diameter (or even larger) is commonly used,
resulting in a search area to target size of 144:1 to 100:1 (or
even lower). In the current study, we used a pool with a diameter
of 104 cm and a platform of 8 cm in diameter, resulting in a
search area to target size of 169:1, thereby increasing the MWM
task difficulty [58,59]. At 12 months of age, when the mice were
exposed to the MWM for the second time, wild-type mice not only
showed a higher preference for the NE target quadrant during the
probe than at 8 months of age, they also persevered in searching
the original platform location during the initial trials in the
rMWM, suggesting that habituation to, and repetition of the
MWM task resulted in enhanced short-term, and formation of
long-term memory for the platform location in wild-type mice.
Standard measures of performance in the MWM as used in the
current study, such as escape latency during acquisition training,
time spent in platform quadrant and the number of platform
crossings during a probe trial, may depend on other factors than
visuo-spatial learning ability and memory capacity alone. Longer
escape latencies during spatial navigation may be caused by slower
swim speed, although we do not expect this to be a confounding
factor, since wild-type and AbPP-PS1 mice did not display any
significant differences in swim speed during the probe trials at any
during training. 12-month-old AbPP-PS1 mice (n = 7) did not improve their performance during acquisition. However, overall latencies did not differ
between the genotypes. F: During the probe trial, the 12-month-old AbPP-PS1 mice traveled a slightly longer distance than wild-type animals,
although it did not reach statistical significance, # trend p= 0.066. G: 12-month-old AbPP-PS1 mice tended to spent less time in the target SW
quadrant, although it did not reach statistical significance, # trend p= 0.066. Only wild-type animals deviated from 25% chance performance level. H:
12-month-old AbPP-PS1 mice crossed the exact former platform location less often than wild-type animals, *p,0.05.
doi:10.1371/journal.pone.0063643.g007
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Figure 8. Neurochemical profile of the hippocampus measured by single voxel 1H MRS at 7 Tesla. A: Representative 1H MR spectra
acquired from the hippocampus of a 12-month-old wild-type mouse. B: Representative 1H MR spectra acquired from the hippocampus of a 12-
month-old AbPPswe-PS1dE9 transgenic mouse. Notice the decreased NAA peak in AbPP-PS1compared to wild-type. C: At 8 months of age, no
differences between wild-type (n = 13) and AbPP-PS1 mice (n = 8) were observed in the hippocampal neurochemical profile. D: At 12 months of age,
AbPP-PS1 mice (n = 4) had significantly lower concentrations of NAA than wild-type mice (n = 7), *p,0.05. tCho= choline-containing compounds;
tCre = creatine and phosphocreatine; Glu =glutamate; Glx = glutamine and glutamate; mI+Gly =myo-Inositol and glycine; NAA=N-acetylaspartate;
Tau= taurine.
doi:10.1371/journal.pone.0063643.g008
Cognition and Proton MRS in Aging APP/PS1 Mice
PLOS ONE | www.plosone.org 12 May 2013 | Volume 8 | Issue 5 | e63643
age. Furthermore, several groups have reported no differences in
swim speed during MWM training between C57BL6/J wild-type
and AbPPswe-PS1dE9 mice at any age tested [60–63]. Longer
escape latencies during spatial navigation may also be caused by
the use of certain, less efficient, search strategies, such as a constant
random search of the entire surface area of the pool, which would
indicate a complete lack of spatial learning abilities, or by
persistent performance of a less efficient than spatial (direct)
search strategy, such as circling the pool at a certain distance from
the wall to find the platform [64–67]. In this strategy, mice have
not used the spatial cues to learn the location of the platform,
although such a strategy would result in a successful location of the
escape platform during training. To our knowledge, the search
strategies used by AbPP-PS1 mice in the MWM have not be
determined yet and should be addressed in future studies to further
characterize the cognitive deficits in the AbPPswe-PS1dE9 mouse
model. However, our results might imply that the AbPP-PS1 mice
made use of a random or persistent non-spatial search strategy to
locate the platform during acquisition training, since AbPP-PS1
mice showed slightly longer escape latencies to find the hidden
platform in the MWM at 8 months of age, searched the target
quadrant during the probe trials at chance level (,25% or less)
and they crossed the former platform location less often than wild-
type mice. In contrast, wild-type mice performed well above
chance level during the probe trials, indicating memorization of
the platform location, which might imply that they made use of a
more spatially precise search strategy. Furthermore, the high
latency of the wild-type mice during the first 2 acquisition trials of
the reversal task at 12 months of age might indicate that they
learned and remembered the original NE platform location quite
well, and persevered in searching the original platform location
during those initial trials in the reversal MWM. The 12-month-old
AbPP-PS1 mice in contrast did not improve their performance
over time in the reversal task, but seemed to perform better in the
first 2 acquisition trials compared to their wild-type littermates.
Again this might imply that the AbPP-PS1 mice made use of a
more random non-spatial search strategy and thereby coinciden-
tally reaching the platform faster than their wild-type littermates.
This is in line with a study by O’Leary and Brown, in which the
search strategies used by 16-month-old AbPP-PS1and wild-type
mice during visuo-spatial navigation in the Barnes Maze were
analyzed [68]. 16-month-old AbPP-PS1 mice predominantly
made use of a random search strategy to locate the escape hole
in the Barnes Maze, whereas wild-type mice predominantly made
use of a spatial (direct and accurate) search strategy. Similar results
have been found for the search strategies used by the TgCRND8
transgenic AbPP mouse model in the MWM test [64,65].
Moreover, it was shown that C57BL6 mice treated with
Temozolomide (TMZ) to suppress adult hippocampal neurogen-
esis, displayed a delayed (or even absent) use of directed and place
specific search patterns in the (reversal) MWM test compared to
untreated mice, suggesting that hippocampal neurogenesis is
necessary for adding flexibility to some hippocampus-dependent
qualitative parameters of learning [67]. Although we did not
observe a significant decrease in the amount of immature neurons
in the 12-month-old AbPP-PS1 mice in our current study, reduced
hippocampal neurogenesis has been found previously in AbPP-
PS1 mice [69–71] and in AD patients [72,73], and might underlie
some aspects of the cognitive deficits in AD.
Synaptic loss is a pathological hallmark of AD, and it is the best
correlate of cognitive impairment [2,74–76]. Synaptophysin is a
widely used marker for quantification of presynaptic terminals, but
conflicting results have been reported on synaptophysin immuno-
reactivity (SYN-IR) both in AD patients [77–80] and AD mouse
models. SYN-IR in transgenic mice that develop Ab plaques has
been reported to decline, increase, or not change, apparently
depending on the interplay of mouse strain, transgene, age, and
disease progression [49,81–86]. In the current study, no changes
were found in the amount of presynaptic boutons at 12 months of
age, similar to earlier reports of no changes in the amount of
presynaptic boutons in 8-month-old AbPP-PS1 mice [42], but in
contrast to the increased amount of presynaptic boutons found in
the hippocampus of 15-month-old AbPP-PS1 mice, which was
suggested to reflect a synaptic compensatory response to maintain
connectivity and preserve cognitive functioning [42]. However, we
did find positive correlations between the levels of high-molecular
weight Ab40 and Ab42 aggregates and the amount of SIPBs in the
SR region of the hippocampus in the 12-month-old AbPP-PS1
mice, which might suggest a possible involvement of Ab aggregates
in the initiation of this synaptic compensatory response. In
contrast, a negative correlation was found between the TBS-T
soluble Ab42 levels and the amount of SIPBs in the PLA region,
which might suggest a possible involvement of soluble Ab
oligomers in synaptic loss. However, these correlations between
the amount of SIPBs and Ab measures did no longer reach
significance when Bonferroni’s correction for multiple compari-
sons was applied. Since the necessity of using the conservative
Figure 9. Amount of synaptophysin-immunoreactive presynaptic boutons (SIPBs) per mm2 in 12-month-old wild-type and AbPP-
PS1 mice. The amount of SIPBs were quantified in the hippocampal inner (IML) and outer molecular layer (OML) of the dentate gyrus, the stratum
radiatum (SR) of the CA1 area, and the stratum lucidum (SL) of the CA3 area, and in the cortical prelimbic area (PLA) and anterior cingulate gyrus
(ACg). No differences in the amount of SIPs between 12-month-old wild-type (n = 9) and AbPP-PS1 mice (n = 6) were observed in any region analyzed
(p.0.10).
doi:10.1371/journal.pone.0063643.g009
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Bonferroni’s adjustment for multiple correlations is still debated
[87–89], these findings must be interpreted with caution.
Recent studies suggest that synapse loss might not be an early
event in the progression of AD, as a decrease in synapses is only
seen in later stages of the disease, where especially tau pathology is
more widespread [90–92]. It has been proposed that the
pathogenesis of synaptic damage in AD can be divided into two
phases: in the first phase, the disease is characterized by neuronal
and synaptic dysfunction (loss of plasticity), which triggers a
compensatory response to maintain connectivity by, first the
formation of new synapses, and later on by increasing the size of
remaining synapses [75,86,90,93]. In the second phase, cycles of
aberrant sprouting and neuritic disorganization eventually result in
synapse loss and neurodegeneration [94,95]. It could be hypoth-
esized that the decreased hippocampal neuronal viability found in
our 12-month-old AbPP-PS1 mice, together with increasing levels
of Ab40 and Ab42 oligomers and aggregates, contribute to synaptic
and neuronal dysfunction, which might trigger a synaptic
compensatory response that in time results in the increased
amount of presynaptic terminals as seen in the hippocampus of 15-
month-old AbPP-PS1 mice [42].
In vivo 1H MRS has been used to characterize cerebral
metabolic alterations in mild cognitive impaired (MCI) individuals
and AD patients [23–25,96–99], and in several transgenic AbPP
animal models for AD [33,100–107]. The most consistent finding
is a decrease in NAA level, a biomarker for neuronal integrity, in
the cortex and hippocampus with aging and disease progression.
Clinically, reduction of NAA has been used as an indicator of the
progression of neurodegenerative pathology in AD patients, and to
differentiate stable MCI from progressive MCI
[23,96,97,108,109]. Longitudinal changes in 1H MRS measures
have also been evaluated in AD patients during therapeutic trials
with cholinergic agents. Treatment with xanomeline, an M1-
selective cholinergic agonist, increased the level of NAA and
decreased the level of Cho compared to baseline values before
treatment. Changes in Cho levels from baseline further correlated
with improved or at least stable ADAS-Cog scores [110,111].
These findings not only support the feasibility of MRS measures in
AD clinical trials, but also indicate that AD-related changes
detected by MRS may be reversible, and may reflect aspects of
neuronal integrity or function. Furthermore, many previous 1H
MRS studies have found increased levels of mI in the temporal,
parietal and occipital lobes of AD patients [22,25,98,99]. mI is a
sugar alcohol that is thought to be a marker for osmotic stress,
astrogliosis and microglial activation [27], and an increase in
cerebral mI levels is therefore associated with inflammatory
processes. Although we did not observe significant differences in
hippocampal mI+Gly concentration between the 12-month-old
wild-type and AbPP-PS1 mice in the current study, correlation
analyses revealed a positive correlation between the levels of Ab40
and Ab42 aggregates and mI+Gly levels in the AbPP-PS1 animals,
suggesting a possible involvement of Ab in inflammatory
processes.
In transgenic animals models, significant reduction of NAA
levels and elevation of mI levels were found to occur at different
ages in different transgenic species apparently depending on the
interplay of mouse strain, transgene and disease progression. The
AbPPswe (Tg2576) model and the AbPPswe-PS2N1411 (PS2APP)
model display significantly decreased NAA level in the frontal
cortex at 19–24 months of age, when Ab deposits are widespread,
but on the other hand no change in mI levels compared to age-
matched wild-type mice [100,102]. In the case of the AbPPswe-
PS1M146L model, a significant reduction in the NAA/tCre ratio
in the frontal hippocampus was observed at 16 month of age in
one study [101], but already at 6.5 months in another study [104],
while the most profound increase in mI level was observed after 20
months of age [101,103,104]. In contrast to our findings of a lower
NAA concentration in the hippocampus of 12-month-old
AbPPswe-PS1dE9 mice, Xu and colleagues did not observe
significantly decreased hippocampal NAA/total creatine (tCre)
levels until 16 months of age, which was associated with
progressive degeneration of CA3 pyramidal neurons [107]. Chen
and colleagues on the other hand observed a significantly lower
concentration of NAA in the frontal cortex and hippocampus
already at 5 months of age in the AbPP-PS1mouse model, which
coincided with neuronal loss and neuronal shrinkage. Further-
more, compared to age-matched wild-type animals the concen-
tration of mI was significantly higher in 3-month-old AbPP-PS1
mice, and pathology showed activation and proliferation of
astrocytes in the frontal cortex and hippocampus [112,113]. The
discrepancy between the results found in the latter two studies and
our findings at 8 and 12 months of age are most likely due to
differences in methodology, e.g. the field strength of the MR
system, the acquisition parameters used, the exact position of the
spectroscopic volume of interest, and the amount of animals
measured.
It has been demonstrated that AbPPswe-PS1dE9 mice may
exhibit various neurobiological abnormalities in the hippocampus
before 8 months of age. Such abnormalities include inflammatory
processes involving clusters of activated microglia and astrocytes,
and TNF-a expression [114], functional pre- and postsynaptic
cholinergic deficits [115], impaired survival of newborn neuronal
cells [116], and increasing levels of insoluble and soluble Ab40 and
Ab42 in parenchyma and vessel walls [36,53,117]. These
neurobiological alterations might underlie the mild behavioral
changes and cognitive decline observed in our 8-month-old AbPP-
PS1 mice in the open field and (r)MWM, since cholinergic
neurotransmission and the integration of newborn neuronal cells
into the circuitry of the hippocampus are important for learning
and memory [67,118,119]. Although we did not observe a
decrease in the amount of immature neurons in our 12-month-
old AbPP-PS1mice, reduced hippocampal neurogenesis has been
found previously in AbPP-PS1 mice beyond 8 months of age [69–
71], as well as expression of IL-1b, IL-6 and MCP-1, suggesting
chronic inflammatory processes [114], decreased cerebral blood
volume (CBV) [34] and gray and white matter degeneration [120].
Increasing levels of Ab together with chronic inflammation and
decreased delivery of oxygen and nutrients (due to cerebral
hypoperfusion) can cause neuronal dysfunction and suppress
hippocampal neurogenesis [17,19,121], thereby contributing to
the more severe cognitive and behavioral dysfunction observed in
our 12-month-old AbPP-PS1 mice alongside with a reduction in
NAA levels measured with 1H MRS. Furthermore, beyond 12
months of age AbPP-PS1 mice display more progressive AD-like
pathology including increased brain-derived neurotrophic factor
(BDNF) levels and lower norepinephrine, serotonin and acetyl-
choline levels [122,123], hippocampal atrophy and a reduced
amount of glucose-transporter type-1 [124], increased amount of
presynaptic boutons [42], and a decrease in CBV [125]. However,
it should be noted that AbPP-PS1 mice do not develop the
widespread neurofibrillary tangle pathology or extensive neuro-
degeneration as seen in AD patients. Thus it is important to use
caution in interpreting results found in AbPP-PS1 (and other
transgenic) mice and translating them to the human AD situation.
To summarize, in this paper we characterized the neurochem-
ical profile of the hippocampus, measured by 1H MRS at 7 Tesla,
in the brains of 8- and 12-month-old AbPPswe-PS1dE9 mice as
compared to age-matched wild-type animals. Our results show
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that at 8 months of age no alterations in hippocampal metabolite
levels could be detected, while behavioral changes and cognitive
decline were present in the AbPP-PS1 mouse model. At 12 months
of age, a decrease in hippocampal NAA levels, reflecting reduced
neuronal integrity, correlated with more severe behavioral and
cognitive impairment in AbPP-PS1 mice as compared to wild-type
animals. Furthermore, correlation analyses suggest a possible role
of Ab in inflammatory processes, synaptic dysfunction and
impaired neurogenesis.
1H MRS could potentially provide unique information about
the underlying degenerative processes, because metabolite levels
are sensitive to different in vivo pathological processes at the
molecular or cellular level. Furthermore, 1H MRS has great
potential for the early diagnosis of AD, monitoring disease
progression and evaluating the efficacy of potential therapeutic
agents, both in animals models and AD patients. However, to
observe small changes related to the disease progression, 1H MRS
data need to be acquired from a large number of mice.
Furthermore, the sensitivity and specificity of 1H MRS depend
on the field strength of the MR system, the acquisition parameters
and the size and position of the spectroscopic volume of interest.
Therefore, we cannot exclude the presence of subtle metabolic
alterations at 8 months of age, since our 1H MRS methodology
may not have been sensitive enough to detect small but important
functional or anatomical abnormalities in the AbPP-PS1mouse
hippocampus.
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